While the model was pitched as a way to lower drug prices, it didn't specify whether drugmakers would have to decrease prices for healthcare providers, meaning providers could have had to offer drugs at a financial loss.

Join The Ecosystem

Leave a Reply

Your email address will not be published. Required fields are marked

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}